Atlas Trials

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Clinical trial NCT06170242 · COMPLETED

Trial details

NCT number
NCT06170242
Sponsor
Enanta Pharmaceuticals, Inc
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
RSV Infection
Start date
2023-11-20
Primary completion
2024-06-17
Enrollment
142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.